GCP
ALLO icon

GSA Capital Partners’s Allogene Therapeutics ALLO Stock Holding History

GSA Capital Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$594K Buy
285,590
+133,868
+88% +$294K 0.04% 881
2026
Q1 		$370K Sell
151,722
-462,276
-75% -$927K 0.02% 1110
2025
Q4 		$841K Buy
613,998
+431,119
+236% +$569K 0.07% 461
2025
Q3 		$227K Sell
182,879
-309,242
-63% -$369K 0.02% 1361
2025
Q2 		$556K Buy
492,121
+8,353
+2% +$11.1K 0.04% 853
2025
Q1 		$706K Buy
+483,768
New +$912K 0.06% 562
2024
Q3 		– Sell
-835,342
Closed -$1.95M – 1565
2024
Q2 		$1.95M Buy
+835,342
New +$2.46M 0.14% 159
2024
Q1 		– Sell
-20,518
Closed -$66K – 1573
2023
Q4 		$66K Sell
20,518
-106,294
-84% -$301K 0.01% 1413
2023
Q3 		$402K Buy
+126,812
New +$556K 0.03% 922
2023
Q1 		– Sell
-251,384
Closed -$1.58M – 1449
2022
Q4 		$1.58M Buy
251,384
+219,538
+689% +$2.03M 0.2% 53
2022
Q3 		$344K Buy
+31,846
New +$433K 0.05% 832
2022
Q2 		– Sell
-148,804
Closed -$1.36M – 1364
2022
Q1 		$1.36M Buy
148,804
+33,989
+30% +$354K 0.18% 83
2021
Q4 		$1.71M Buy
+114,815
New +$2.03M 0.22% 46
2021
Q3 		– Sell
-13,951
Closed -$364K – 1386
2021
Q2 		$364K Buy
+13,951
New +$398K 0.04% 817
2021
Q1 		– Sell
-11,273
Closed -$285K – 1070
2020
Q4 		$285K Buy
+11,273
New +$367K 0.05% 767
2020
Q1 		– Sell
-10,622
Closed -$276K – 1026
2019
Q4 		$276K Buy
+10,622
New +$293K 0.03% 1079

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

GSA Capital Partners's ALLO Position: Q2 2026 in Review

GSA Capital Partners increased its Allogene Therapeutics (ALLO) stake by 88% in Q2 2026, buying an estimated $294K and bringing the position to 285,590 shares worth $594K. The position accounts for 0.04% of the portfolio, ranked #881.

GSA Capital Partners first reported a position in ALLO in Q4 2019 and has held it in 16 quarters since. The position peaked at $1.95M in Q2 2024. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • GSA Capital Partners held 285,590 shares of Allogene Therapeutics worth $594K as of Q2 2026.
  • GSA Capital Partners bought 133,868 Allogene Therapeutics shares in Q2 2026, an estimated $294K.
  • Allogene Therapeutics made up 0.04% of GSA Capital Partners's portfolio in Q2 2026, its #881 holding.
  • GSA Capital Partners first reported a position in Allogene Therapeutics in Q4 2019 and has held it in 16 quarters since.
  • GSA Capital Partners's Allogene Therapeutics position peaked at $1.95M in Q2 2024.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.